Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir PK and Safety in Pediatric HIV
NCT01302847Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2011
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2011; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01302847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302847.